(0.37%) 5 118.98 points
(0.29%) 38 350 points
(0.40%) 15 991 points
(-0.52%) $83.41
(2.96%) $1.980
(0.02%) $2 347.70
(-0.01%) $27.53
(3.16%) $951.25
(-0.07%) $0.934
(-0.10%) $11.01
(-0.33%) $0.798
(1.74%) $93.48
@ $26.12
发出时间: 11 Apr 2024 @ 03:05
回报率: -4.40%
上一信号: Apr 10 - 01:08
上一信号:
回报率: -2.68 %
Live Chart Being Loaded With Signals
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally...
Stats | |
---|---|
今日成交量 | 77 249.00 |
平均成交量 | 2.01M |
市值 | 4.17B |
EPS | $0 ( 2024-04-24 ) |
下一个收益日期 | ( $0 ) 2024-07-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 8.16 |
ATR14 | $0.0490 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Lurker Nancy | Buy | 22 103 | Non Qualified Stock Option (Right to Buy) |
2024-04-11 | Lurker Nancy | Buy | 11 255 | Restricted Stock Unit Award |
2024-04-11 | Lurker Nancy | Buy | 4 833 | Non Qualified Stock Option (Right to Buy) |
2024-04-11 | Lurker Nancy | Buy | 2 323 | Restricted Stock Unit Award |
2024-03-18 | Nichols Christian Todd | Sell | 10 417 | Ordinary Shares |
INSIDER POWER |
---|
75.16 |
Last 99 transactions |
Buy: 1 207 179 | Sell: 170 568 |
音量 相关性
Alkermes Plc 相关性 - 货币/商品
Alkermes Plc 财务报表
Annual | 2023 |
营收: | $1.66B |
毛利润: | $1.37B (82.64 %) |
EPS: | $2.14 |
FY | 2023 |
营收: | $1.66B |
毛利润: | $1.37B (82.64 %) |
EPS: | $2.14 |
FY | 2022 |
营收: | $1.11B |
毛利润: | $893.69M (80.38 %) |
EPS: | $-0.970 |
FY | 2021 |
营收: | $1.17B |
毛利润: | $569.84M (48.55 %) |
EPS: | $-0.300 |
Financial Reports:
No articles found.
Alkermes Plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。